Pacer Advisors
MRSN

Pacer Advisors’s Mersana Therapeutics MRSN Stock Holding History

Pacer Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-69
Closed -$7.69K – 3775
2024
Q1 		$7.69K Buy
+69
New +$6.86K ﹤0.01% 3567
2021
Q2 		– Sell
-173
Closed -$70K – 1495
2021
Q1 		$70K Buy
173
+3
+2% +$1.46K ﹤0.01% 1370
2020
Q4 		$113K Buy
170
+118
+227% +$65.6K ﹤0.01% 1348
2020
Q3 		$24K Buy
+52
New +$26.3K ﹤0.01% 1349

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacer Advisors's MRSN Position: Q2 2024 in Review

Pacer Advisors sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 69 shares — an estimated $7.69K sold.

Pacer Advisors first reported a position in MRSN in Q3 2020 and held it in 4 quarters. The position peaked at $113K in Q4 2020. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Pacer Advisors reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Pacer Advisors sold 69 Mersana Therapeutics shares in Q2 2024, an estimated $7.69K.
  • Pacer Advisors first reported a position in Mersana Therapeutics in Q3 2020 and held it in 4 quarters.
  • Pacer Advisors's Mersana Therapeutics position peaked at $113K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.